ReviewJournal of pharmaceutical analysis2024
Targeting NTCP for liver disease treatment: A promising strategy.
Review in Journal of pharmaceutical analysis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Review
- Post-Translational Modifications of NTCP: A Regulatory Nexus for Bile Acid Transport and HBV Entry.Biomedicines · 2026Review
- Problems associated with the ATC system of drug classification.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.Hepatology (Baltimore, Md.) · 2025Review
- Gut microbiome and bile acid changes after male rodent sleeve gastrectomy: what comes first?American journal of physiology. Regulatory, integrative and comparative physiology · 2025Article
- Association of rs4646287 Polymorphism with the Risk of Hepatitis B Virus Infection and the Progression of Hepatocellular Carcinoma in an Iranian Population.Iranian biomedical journal · 2025Article
- Functional Food Ge-Zhi Soup Ameliorates Acute Liver Injury Through the AKT/GSK3β/PPARα Pathway.Food science & nutrition · 2025Article
- The Correlation Between NTCP rs2296651 Variant and Risk of Hepatitis B, Cirrhosis, and Hepatocellular Carcinoma in Iranian Population.Middle East journal of digestive diseases · 2025Article
- Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System.Cells · 2025Article
- Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions.Pharmaceutics · 2025Review
- Bile acids as therapeutic agents.Frontiers in pharmacology · 2025Review
- Emodin and physcion alleviate cholestatic liver injury by targeting FXR: hepatoprotective components identified in processedFrontiers in pharmacology · 2025Article
- Silicon-Enriched Meat Ameliorates Diabetic Dyslipidemia by Improving Cholesterol, Bile Acid Metabolism and Ileal Barrier Integrity in Rats with Late-Stage Type 2 Diabetes.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sodium taurocholate co-transporting polypeptide (NTCP), a bile acids transporter, has been identified as a new therapeutic target for the treatment of liver disease. This paper thoroughly investigates the function of NTCP for regulating bile acid regulation, its correlation with hepatitis B and D infections, and its association with various liver diseases. Additionally, in this review we examine recent breakthroughs in creating NTCP inhibitors and their prospective applications in liver disease treatment. While this review emphasizes the promising potential of targeting NTCP, it concurrently underscores the need for broader and more detailed research to fully understand the long-term implications and potential side effects associated with NTCP inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.